JP7430141B2 - 化学療法誘発性の医原性疼痛の治療に使用するためのＣ５ａＲ阻害薬 - Google Patents

化学療法誘発性の医原性疼痛の治療に使用するためのＣ５ａＲ阻害薬 Download PDF

Info

Publication number
JP7430141B2
JP7430141B2 JP2020532696A JP2020532696A JP7430141B2 JP 7430141 B2 JP7430141 B2 JP 7430141B2 JP 2020532696 A JP2020532696 A JP 2020532696A JP 2020532696 A JP2020532696 A JP 2020532696A JP 7430141 B2 JP7430141 B2 JP 7430141B2
Authority
JP
Japan
Prior art keywords
phenyl
induced
chemotherapy
group
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020532696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505647A (ja
JP2021505647A5 (enExample
Inventor
ブランドリーニ，ローラ
クーニャ，ティアゴ・マター
アレグレッティ，マルチェッロ
アラミーニ，アンドレア
ビアンチーニ，ジャンルーカ
Original Assignee
ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ filed Critical ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Publication of JP2021505647A publication Critical patent/JP2021505647A/ja
Publication of JP2021505647A5 publication Critical patent/JP2021505647A5/ja
Priority to JP2023211061A priority Critical patent/JP2024028984A/ja
Application granted granted Critical
Publication of JP7430141B2 publication Critical patent/JP7430141B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020532696A 2017-12-12 2018-12-11 化学療法誘発性の医原性疼痛の治療に使用するためのＣ５ａＲ阻害薬 Active JP7430141B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023211061A JP2024028984A (ja) 2017-12-12 2023-12-14 化学療法誘発性の医原性疼痛の治療に使用するためのＣ５ａＲ阻害薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17206813.2 2017-12-12
EP17206813.2A EP3498269A1 (en) 2017-12-12 2017-12-12 C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
PCT/EP2018/084277 WO2019115493A2 (en) 2017-12-12 2018-12-11 C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023211061A Division JP2024028984A (ja) 2017-12-12 2023-12-14 化学療法誘発性の医原性疼痛の治療に使用するためのＣ５ａＲ阻害薬

Publications (3)

Publication Number Publication Date
JP2021505647A JP2021505647A (ja) 2021-02-18
JP2021505647A5 JP2021505647A5 (enExample) 2022-01-11
JP7430141B2 true JP7430141B2 (ja) 2024-02-09

Family

ID=60673204

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020532696A Active JP7430141B2 (ja) 2017-12-12 2018-12-11 化学療法誘発性の医原性疼痛の治療に使用するためのＣ５ａＲ阻害薬
JP2023211061A Pending JP2024028984A (ja) 2017-12-12 2023-12-14 化学療法誘発性の医原性疼痛の治療に使用するためのＣ５ａＲ阻害薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023211061A Pending JP2024028984A (ja) 2017-12-12 2023-12-14 化学療法誘発性の医原性疼痛の治療に使用するためのＣ５ａＲ阻害薬

Country Status (13)

Country Link
US (2) US12102607B2 (enExample)
EP (2) EP3498269A1 (enExample)
JP (2) JP7430141B2 (enExample)
KR (2) KR20200108839A (enExample)
CN (1) CN111511363A (enExample)
AU (1) AU2018385364B2 (enExample)
BR (1) BR112020009972A2 (enExample)
CA (1) CA3082762A1 (enExample)
IL (1) IL275132A (enExample)
MA (1) MA51128A (enExample)
RU (1) RU2020122678A (enExample)
SG (1) SG11202004322VA (enExample)
WO (1) WO2019115493A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4308114A1 (en) * 2021-03-17 2024-01-24 Dompe' Farmaceutici SpA C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4397306A1 (en) * 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517368A (ja) 2005-11-24 2009-04-30 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ （ｒ）−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物
JP2011500643A (ja) 2007-10-18 2011-01-06 ドムペ・ソチエタ・ペル・アツィオーニ （ｒ）−４−（ヘテロアリール）フェニルエチル誘導体及びそれらを含有する医薬組成物
WO2017121838A1 (en) 2016-01-15 2017-07-20 Dompe' Farmaceutici S.P.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1934077B (zh) * 2004-03-23 2010-09-29 冬姆佩制药股份公司 2-苯基丙酸衍生物及含有它们的药物组合物
SG187396A1 (en) 2007-07-19 2013-02-28 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
EP3192504A1 (en) * 2016-01-15 2017-07-19 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517368A (ja) 2005-11-24 2009-04-30 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ （ｒ）−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物
JP2011500643A (ja) 2007-10-18 2011-01-06 ドムペ・ソチエタ・ペル・アツィオーニ （ｒ）−４−（ヘテロアリール）フェニルエチル誘導体及びそれらを含有する医薬組成物
WO2017121838A1 (en) 2016-01-15 2017-07-20 Dompe' Farmaceutici S.P.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIJUN XU ET AL，ROLE OF COMPLEMENT IN PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY，THE ANESTHESIOLOGY ANNUAL MEETIING，[2022年11月15日検索]，AMERICAN SOCIETY OF ANESTHESIOLOGISTS，2017年10月22日，A2227，http://www.asaabstracts.com/strands/asaabstracts/abstract.htm?year=2017&index=3&absnum=3878

Also Published As

Publication number Publication date
RU2020122678A (ru) 2022-01-13
MA51128A (fr) 2021-03-24
RU2020122678A3 (enExample) 2022-02-15
JP2024028984A (ja) 2024-03-05
AU2018385364B2 (en) 2024-04-04
KR20200108839A (ko) 2020-09-21
JP2021505647A (ja) 2021-02-18
CN111511363A (zh) 2020-08-07
BR112020009972A2 (pt) 2021-02-09
WO2019115493A2 (en) 2019-06-20
WO2019115493A3 (en) 2019-07-25
SG11202004322VA (en) 2020-07-29
IL275132A (en) 2020-07-30
US12102607B2 (en) 2024-10-01
US20200397725A1 (en) 2020-12-24
EP3723744A2 (en) 2020-10-21
EP3498269A1 (en) 2019-06-19
CA3082762A1 (en) 2019-06-20
US20240398731A1 (en) 2024-12-05
KR20250041193A (ko) 2025-03-25
AU2018385364A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
Bamps et al. TRP channel cooperation for nociception: therapeutic opportunities
JP2024028984A (ja) 化学療法誘発性の医原性疼痛の治療に使用するためのＣ５ａＲ阻害薬
US11963957B2 (en) Treating cardiovascular disease by selectively eliminating senescent cells
US9095609B2 (en) Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia
RU2770050C2 (ru) Способ лечения с применением традипитанта
US20220184075A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
US20180311236A1 (en) Use of masitinib and other mast cell inhibitors for treatment of parkinson&#39;s disease
WO2013009810A1 (en) Methods of treatment
JP2013516442A (ja) 肥満症に用いる小分子
WO2008028903A2 (en) Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
Trevisani et al. TRPV1 antagonists as analgesic agents
BR112014025251B1 (pt) uso de um ativador de troponina de músculo esquelético e composição compreendendo o mesmo
CN109415342A (zh) 用于治疗纤维化的wnt抑制剂
Tichy et al. New light on an old friend: Targeting PUMA in radioprotection and therapy of cardiovascular and neurodegenerative diseases
RU2536270C1 (ru) Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс
Cech et al. Therapeutic potential of senotherapeutics
Danani et al. Heat Shock Proteins: Novel Targets for CNS Disorders
RS60669B1 (sr) Kombinacija inverznih agonista histamin-3 receptora sa inhibitorima acetilholinesteraze
RU2810253C2 (ru) Способ лечения с применением традипитанта
Rezk et al. Histopathological Effects of Therapeutic Doses of Combined XO-Inhibitors and ACE-Inhibitors on the Expression of VEGF-A in the Myocardium and Renal Cortex in Chronic Hypertensive Albino Rats
Al-Kharrat et al. Using Calcitonin Gene-related Peptide Monoclonal Antibodies for Migraine Headache Treatment and Prevention
CN118161473A (zh) Isrib在制备防治缺血性脑卒中药物中的应用
IL170743A (en) Use of amino acid pyridine-2-ylmethyl histories for the treatment of chronic pain symptoms of neuropathological or psychogenic origin
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов
EA042129B1 (ru) Применение ингибиторов ил-8 в лечении периферической нейропатии, вызванной химиотерапией

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231214

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240130

R150 Certificate of patent or registration of utility model

Ref document number: 7430141

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150